Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

none61BACKGROUND: Benefits of conversion from calcineurin inhibitor (CNI) to mammalian target of rapamycin inhibitor-based immunosuppression in long-term kidney transplant patients remain uncertain. METHODS: ASCERTAIN was a 24-month, open-label, multicenter study. Kidney transplant patients more than 6 months posttransplant receiving CNI (baseline glomerular filtration rate [GFR] 30-70 mL/min/1.73 m) were randomized to everolimus with CNI elimination (n=127) or CNI minimization (n=144), or continued CNI unchanged (controls, n=123) to assess the effect on measured GFR at month 24 after randomization. RESULTS: Renal function was stable in all groups to month 24. Mean measured GFR at month 24, the primary endpoint, was 48.0±22.0 mL/min/1.73 m, 46.6±21.1 mL/min/1.73 m, and 46.0±20.4 mL/min/1.73 m in the CNI elimination, CNI minimization, and control groups, respectively. Differences between CNI elimination (1.12 mL/min/1.73 m, 95% confidence interval [CI] -3.51 to 5.76, P=0.63) and CNI minimization (0.59 mL/min/1.73 m, 95% CI -3.88 to 5.07, P=0.79) versus controls at month 24 were nonsignificant that is, the primary endpoint was not met. No efficacy endpoint differed significantly between groups. Post hoc analyses showed that patients with baseline creatinine clearance (CrCl) more than 50 mL/min had a significantly greater increase in measured GFR after CNI elimination versus controls (difference 11.4 mL/min/1.73 m, 95% CI 2.1 to 20.8 mL/min/1.73 m, P=0.017). Adverse events resulted in discontinuation in 36 (28.3%) CNI elimination patients, 24 (16.7%) CNI minimization patients, and 5 (4.1%) controls (P<0.001 vs. CNI elimination; P=0.020 vs. CNI minimization). CONCLUSION: Conversion to everolimus with CNI elimination or minimization a mean of 5.6 years after kidney transplantation had no overall renal benefit and was associated with more frequent adverse events and discontinuations. Patients with CrCl more than 50 mL/min may benefit from a change in therapy more than 6 months after renal transplantation.mixedHoldaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ; Toselli L; Eris J; Fassett R; Faull R; Goodman D; Hutchison B; Kanellis J; O'Connell P; Ranganathan D; Russ G; Suranyi M; Walker R; Goffin E; Vanrenterghem Y; Kapoor A; Karpinski M; Dantal J; Boletis I; Takoudas D; Ballal S; John GT; Kher V; Sharma RK; Sundar S; Thiagrajan CM; Cancarini G; Carmellini M; Messa P; Piredda G; Sparacino V; Stefoni S; Hene RJ; Heldal K; Høyeggen A; Laegreid I; Svarstad E; Arias M; Oppenheimer F; Seron D; Chu SH; Lian JD; Lee PH; Shu KH; Yang WC; Praditpornsilpa K; Gonenc F; Gurkan A; Toz H.Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ; Toselli L; Eris J; Fassett R; Faull R; Goodman D; Hutchison B; Kanellis J; O'Connell P; Ranganathan D; Russ G; Suranyi M; Walker R; Goffin E; Vanrenterghem Y; Kapoor A; Karpinski M; Dantal J; Boletis I; Takoudas D; Ballal S; John GT; Kher V; Sharma RK; Sundar S; Thiagrajan CM; Cancarini G; Carmellini M; Messa P; Piredda G; Sparacino V; Stefoni S; Hene RJ; Heldal K; Høyeggen A; Laegreid I; Svarstad E; Arias M; Oppenheimer F; Seron D; Chu SH; Lian JD; Lee PH; Shu KH; Yang WC; Praditpornsilpa K; Gonenc F; Gurkan A; Toz H